Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | BACE1 | P56817 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361480 | 0.98 | KDM4E (0.83) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL14426319 | 0.95 | KDM4E (0.78) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL11983507 | 0.92 | KDM4E (1.00) | KDM4EL3MBTL1ALDH1A1TSHRESR1 | |
| SCHEMBL8266135 | 0.91 | BACE1 (0.77) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL12660177 | 0.91 | KDM4E (0.91) | KDM4EL3MBTL1ALDH1A1TSHRHRH3 | |
| SCHEMBL12810770 | 0.88 | KMT2A (0.69) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL13766381 | 0.85 | KDM4E (0.63) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL259183 | 0.85 | KDM4E (0.63) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL14970714 | 0.84 | HRH3 (0.76) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 | |
| SCHEMBL15474805 | 0.84 | HRH3 (0.76) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| WO-2008044144-A2 | CHIRAL TETRA-HYDRO BETA-CARBOLIC DERIVATIVES AND APPLICATIONS THEREOF AS ANTIPARASITIC COMPOUNDS | UNIVERSITE DE LILLE 2, UNIVERSITÉ DU DROIT ET DE LA SANTÉ (FR) | 2008-04-17 | — | — | WO | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | KDM4E 2344/4885L3MBTL1 1326/4885ALDH1A1 208/4885 |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885L3MBTL1 3823/4885ALDH1A1 835/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | KDM4E 2970/4885L3MBTL1 4071/4885ALDH1A1 1154/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885L3MBTL1 3455/4885ALDH1A1 709/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KDM4E 2196/4885L3MBTL1 3535/4885ALDH1A1 4428/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885L3MBTL1 3455/4885ALDH1A1 709/4885 |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KDM4E 1105/4885L3MBTL1 3455/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.